

Sarah L Larney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5077842/publications.pdf>

Version: 2024-02-01

147
papers

6,746
citations

94433

37
h-index

71685

76
g-index

149
all docs

149
docs citations

149
times ranked

6531
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	6.3	1,020
2	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
3	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	13.7	404
4	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1208-e1220.	6.3	334
5	Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. <i>Hepatology</i> , 2013, 58, 1215-1224.	7.3	263
6	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1385-1398.	9.1	223
7	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	3.3	178
8	Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. <i>Lancet, The</i> , 2015, 386, 350-359.	13.7	172
9	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. <i>Addiction</i> , 2014, 109, 1306-1317.	3.3	165
10	A systematic review of injecting-related injury and disease among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 171, 39-49.	3.2	163
11	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	8.1	145
12	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. <i>Lancet Psychiatry, the</i> , 2015, 2, 901-908.	7.4	106
13	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. <i>Addiction</i> , 2014, 109, 90-99.	3.3	92
14	Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. <i>Addiction</i> , 2012, 107, 372-380.	3.3	89
15	Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
16	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	11.0	83
17	Estimating the number of regular and dependent methamphetamine users in Australia, 2002-2014. <i>Medical Journal of Australia</i> , 2016, 204, 153-153.	1.7	78
18	A cross-sectional survey of prevalence and correlates of suicidal ideation and suicide attempts among prisoners in New South Wales, Australia. <i>BMC Public Health</i> , 2012, 12, 14.	2.9	76

#	ARTICLE	IF	CITATIONS
19	Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. <i>Addiction</i> , 2010, 105, 216-223.	3.3	70
20	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	3.3	67
21	A Literature Review of International Implementation of Opioid Substitution Treatment in Prisons: Equivalence of Care?. <i>European Addiction Research</i> , 2009, 15, 107-112.	2.4	64
22	A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. <i>Drug and Alcohol Dependence</i> , 2018, 184, 57-63.	3.2	64
23	Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. <i>Addiction</i> , 2016, 111, 2177-2186.	3.3	61
24	A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. <i>Addiction</i> , 2015, 110, 646-655.	3.3	57
25	Changes in Youth Mental Health, Psychological Wellbeing, and Substance Use During the COVID-19 Pandemic: A Rapid Review. <i>Adolescent Research Review</i> , 2022, 7, 161-177.	4.5	56
26	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. <i>BMJ Open</i> , 2014, 4, e004666.	1.9	54
27	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	3.3	54
28	Mortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000-2011. <i>Drug and Alcohol Dependence</i> , 2015, 147, 32-37.	3.2	52
29	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
30	Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S155-S161.	2.1	49
31	A rapid review of the impacts of "Big Events" on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. <i>International Journal of Drug Policy</i> , 2021, 92, 103127.	3.3	47
32	Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S100-S109.	2.1	46
33	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	3.3	46
34	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
35	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <i>American Journal of Public Health</i> , 2020, 110, 45-50.	2.7	44
36	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107793.	3.2	44

#	ARTICLE	IF	CITATIONS
37	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. <i>International Journal of Drug Policy</i> , 2015, 26, 950-957.	3.3	42
38	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. <i>Drug and Alcohol Review</i> , 2014, 33, 115-128.	2.1	41
39	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	5.8	39
40	Estimating the number of people who inject drugs in Australia. <i>BMC Public Health</i> , 2017, 17, 757.	2.9	38
41	To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555.	1.9	35
42	Geographic variability in HIV and injection drug use in Ukraine: Implications for integration and expansion of drug treatment and HIV care. <i>International Journal of Drug Policy</i> , 2015, 26, 37-42.	3.3	32
43	A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2017, 36, 305-310.	2.1	32
44	Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. <i>Addiction</i> , 2019, 114, 1738-1750.	3.3	32
45	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
46	Evaluating Health Outcomes of Criminal Justice Populations Using Record Linkage: The Importance of Aliases. <i>Evaluation Review</i> , 2011, 35, 118-128.	1.0	29
47	A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. <i>Addiction</i> , 2015, 110, 1975-1984.	3.3	29
48	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health</i> , The, 2019, 4, e334-e342.	10.0	29
49	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. <i>Journal of Infectious Diseases</i> , 2019, 220, 78-90.	4.0	29
50	Factors associated with violent victimisation among homeless adults in Sydney, Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2009, 33, 347-351.	1.8	27
51	Epidemiology of Hepatitis C Virus in Pennsylvania State Prisons, 2004–2012: Limitations of 1945–1965 Birth Cohort Screening in Correctional Settings. <i>American Journal of Public Health</i> , 2014, 104, e69-e74.	2.7	26
52	Yes, people can die from opiate withdrawal. <i>Addiction</i> , 2017, 112, 199-200.	3.3	26
53	The impact of personality disorders, substance use and other mental illness on re-offending. <i>Journal of Forensic Psychiatry and Psychology</i> , 2012, 23, 382-391.	1.0	24
54	The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. <i>Drug and Alcohol Dependence</i> , 2013, 131, 252-257.	3.2	24

#	ARTICLE	IF	CITATIONS
55	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	2.9	22
56	Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health care system. <i>Drug and Alcohol Review</i> , 2019, 38, 264-269.	2.1	21
57	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	3.3	21
58	All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 725-742.	3.3	21
59	Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Addiction</i> , 2013, 108, 2152-2165.	3.3	20
60	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017, 46, 7-16.	3.3	20
61	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	3.3	20
62	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <i>Lancet Psychiatry</i> , 2021, 8, 301-309.	7.4	20
63	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	6.3	19
64	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 90-96.	2.1	18
65	Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1123-1133.	2.4	18
66	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	3.2	18
67	Seek, test, treat and retain for hepatitis C in the United States criminal justice system. <i>International Journal of Prisoner Health</i> , 2014, 10, 164-171.	0.9	17
68	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. <i>BMJ Open</i> , 2018, 8, e025840.	1.9	17
69	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	3.3	17
70	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 87-93.	3.3	16
71	Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2017, 47, 102-106.	3.3	15
72	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	3.3	14

#	ARTICLE	IF	CITATIONS
73	Compulsory detoxification is a major challenge to harm reduction in China. <i>International Journal of Drug Policy</i> , 2010, 21, 165-166.	3.3	13
74	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1047-1055.	3.0	13
75	Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108267.	3.2	13
76	Hepatitis C antibody prevalence among Mexico City prisoners injecting legal and illegal substances. <i>Drug and Alcohol Dependence</i> , 2017, 181, 140-145.	3.2	12
77	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	3.4	12
78	The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108189.	2.8	12
79	Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map. <i>Addiction</i> , 2022, 117, 2168-2188.	3.3	12
80	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109494.	3.2	12
81	Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 148, 213-216.	3.2	11
82	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <i>Addiction</i> , 2018, 113, 1768-1774.	3.3	11
83	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	2.0	11
84	Protocol for the Data-Linkage Alcohol Cohort Study (DACS): investigating mortality, morbidity and offending among people with an alcohol-related problem using linked administrative data. <i>BMJ Open</i> , 2019, 9, e030605.	1.9	11
85	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	3.3	11
86	Trends in comorbid opioid and stimulant use disorders among Veterans receiving care from the Veterans Health Administration, 2005-2019. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109310.	3.2	11
87	Factors affecting criminal recidivism among participants in the Magistrates Early Referral Into Treatment (MERIT) program in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2010, 29, 684-688.	2.1	10
88	Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: comparison of Indigenous and non-Indigenous Australians. <i>BMC Public Health</i> , 2014, 14, 920.	2.9	10
89	Imprisonment of opioid-dependent people in New South Wales, Australia, 2000-2012: a retrospective linkage study. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 165-170.	1.8	10
90	The ethics of hepatitis C treatment as prevention among prisoners. <i>Hepatology</i> , 2015, 61, 402-402.	7.3	10

#	ARTICLE	IF	CITATIONS
91	Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012. <i>Journal of Correctional Health Care</i> , 2016, 22, 41-45.	0.5	10
92	A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. <i>Lancet Public Health</i> , The, 2019, 4, e77-e78.	10.0	10
93	All-Cause and Overdose Mortality Risk Among People Prescribed Opioids: A Systematic Review and Meta-analysis. <i>Pain Medicine</i> , 2020, 21, 3700-3711.	1.9	10
94	Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1694-1701.	3.0	10
95	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
96	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
97	A gender lens is needed in hepatitis C elimination research. <i>International Journal of Drug Policy</i> , 2022, 103, 103654.	3.3	10
98	Inadequate data collection prevents health planning for released prisoners. <i>Medical Journal of Australia</i> , 2009, 191, 408-409.	1.7	9
99	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	3.3	9
100	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109050.	3.2	9
101	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. <i>International Journal of Population Data Science</i> , 2020, 5, 1145.	0.1	9
102	Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada. <i>Harm Reduction Journal</i> , 2022, 19, 38.	3.2	9
103	Residential detoxification: essential for marginalised, severely alcohol- and drug-dependent individuals. <i>Drug and Alcohol Review</i> , 2008, 27, 414-419.	2.1	8
104	An exploratory study of needlestick injuries among Australian prison officers. <i>International Journal of Prisoner Health</i> , 2008, 4, 164-168.	0.9	8
105	A cross-sectional study of susceptibility to vaccine-preventable diseases among prison entrants in New South Wales. <i>Medical Journal of Australia</i> , 2013, 198, 376-379.	1.7	8
106	A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations. <i>Annals of Epidemiology</i> , 2016, 26, 570-578.e2.	1.9	8
107	A population-based study of transdermal fentanyl initiation in Australian clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 401-408.	1.9	8
108	Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. <i>Australian and New Zealand Journal of Public Health</i> , 2008, 32, 86-87.	1.8	7

#	ARTICLE	IF	CITATIONS
109	Presence of hepatitis C virus in syringes confiscated in prisons in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1655-1657.	2.8	7
110	A review of HIV in prisons in Nepal. <i>Kathmandu University Medical Journal</i> , 2010, 7, 351-354.	0.2	7
111	A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 686-692.	2.1	7
112	Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2019, 38, 690-698.	2.1	7
113	What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 420-429.	2.1	7
114	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7
115	An estimate of the number of inmate separations from Australian prisons 2000/01 and 2005/06. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 255-257.	1.8	6
116	Prisoner suicide: a multilevel problem. <i>Lancet Psychiatry</i> , 2017, 4, 894-895.	7.4	6
117	Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. <i>Pain Medicine</i> , 2018, 19, 1170-1183.	1.9	6
118	HIV in Indian prisons: risk behaviour, prevalence, prevention & treatment. <i>Indian Journal of Medical Research</i> , 2010, 132, 696-700.	1.0	6
119	Health outcomes, program completion, and criminal recidivism among participants in the Rural Alcohol Diversion program, Australia. <i>Journal of Substance Use</i> , 2011, 16, 50-56.	0.7	5
120	Unknown Quantities. <i>Sexually Transmitted Diseases</i> , 2014, 41, 283.	1.7	5
121	Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108343.	3.2	5
122	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
123	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. <i>Drug and Alcohol Dependence</i> , 2018, 188, 304-310.	3.2	4
124	Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. <i>Drug and Alcohol Review</i> , 2021, 40, 1349-1353.	2.1	4
125	Mapping drug epidemiology futures. <i>International Journal of Drug Policy</i> , 2021, 94, 103378.	3.3	4
126	Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109091.	3.2	4

#	ARTICLE	IF	CITATIONS
127	Increasing numbers of inmate separations from Australian prisons. <i>Medical Journal of Australia</i> , 2012, 196, 110-110.	1.7	3
128	A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. <i>Drug and Alcohol Review</i> , 2014, 33, 499-505.	2.1	3
129	Variation in mortality risk of people released from prison. <i>Lancet Psychiatry</i> , 2015, 2, 681.	7.4	3
130	A Systematic Review of Supported Accommodation Programs for People Released From Custody. <i>International Journal of Offender Therapy and Comparative Criminology</i> , 2018, 62, 2174-2194.	1.2	3
131	Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia. <i>Drug and Alcohol Review</i> , 2020, 39, 83-92.	2.1	3
132	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	3.2	3
133	Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2021, 40, 98-108.	2.1	3
134	Initiation of Medications for Opioid Use Disorder Shortly Before Release From Prison to Promote Treatment Retention: Strong Evidence but Compromised Policy. <i>Journal of Addiction Medicine</i> , 2021, 15, 525-526.	2.6	3
135	Hepatitis C Prevention and Needle Exchange Programs in Rhode Island: ENCORE. <i>Rhode Island Medical Journal</i> (2013), 2014, 97, 31-4.	0.2	3
136	Trends in opioid analgesic utilisation among people with a history of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109548.	3.2	3
137	Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007-2013. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 58-63.	2.8	2
138	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
139	The association between involuntary alcohol treatment and subsequent emergency department visits and hospitalisations: a Bayesian analysis of treated patients and matched controls. <i>Addiction</i> , 2021, , .	3.3	2
140	Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison. <i>International Journal of Drug Policy</i> , 2022, 100, 103572.	3.3	2
141	Editorial Commentary: Hepatitis C Virus Testing and Drug Use in North America; Is There More Than Meets the Eye?. <i>Clinical Infectious Diseases</i> , 2014, 58, 762-764.	5.8	1
142	Reply. <i>Hepatology</i> , 2014, 59, 733-734.	7.3	1
143	HIV Prevention, Treatment, and Care for People Who Inject Drugs. <i>Journal of Infectious Diseases</i> , 2013, 208, 370-372.	4.0	0
144	Methadone for prisoners - Authors' reply. <i>Lancet</i> , 2016, 387, 225.	13.7	0

#	ARTICLE	IF	CITATIONS
145	Response to Bird <i>et al</i> .: The importance of post-release engagement in treatment in estimating impacts on post-release deaths. <i>Addiction</i> , 2016, 111, 560-561.	3.3	0
146	Commentary on Binswanger <i>et al</i> . (2016): Multiple opportunities exist to improve the health and wellbeing of people released from prisons. <i>Addiction</i> , 2016, 111, 511-512.	3.3	0
147	Commentary on McDonald <i>et al</i> . (2018): Intranasal naloxone "from the laboratory to the real world. <i>Addiction</i> , 2018, 113, 494-495.	3.3	0